Pediapharm Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Medexus Pharmaceuticals Inc (MDP)
Medexus Pharmaceuticals Inc stock price live, this page displays TSX MDP stock exchange data. View the MDP premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Medexus Pharmaceuticals Inc real time stock price chart below.
What Is the Medexus Pharmaceuticals Inc Stock Price Today?
The Medexus Pharmaceuticals Inc stock price today is 4.98.
What Is the Stock Symbol for Medexus Pharmaceuticals Inc?
The stock symbol for Medexus Pharmaceuticals Inc is "MDP."
What Stock Exchange Does Medexus Pharmaceuticals Inc Trade On?
Medexus Pharmaceuticals Inc is listed and trades on the Toronto stock exchange.
Is Medexus Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Medexus Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the MDP quote. (ISIN: CA58410Q2036)
What Is the Medexus Pharmaceuticals Inc Stock Price Today?
The Medexus Pharmaceuticals Inc stock price today is 4.98.
What Is the Stock Symbol for Medexus Pharmaceuticals Inc?
The stock symbol for Medexus Pharmaceuticals Inc is "MDP."
What Stock Exchange Does Medexus Pharmaceuticals Inc Trade On?
Medexus Pharmaceuticals Inc is listed and trades on the Toronto stock exchange.
Is Medexus Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Medexus Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the MDP quote. (ISIN: CA58410Q2036)
4.98
+0.01(+0.20%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.94
5.01
52 wk Range
2.47
5.25
MDP is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.945.01
52 wk Range
2.475.25
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
MDP Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
6.81
Upside
+36.75%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Net income is expected to grow this year
Pediapharm Inc receives Investment Bank Analyst Rating Update- Investing.com
Pro
- Pediapharm Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Pediapharm Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro 
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Strong Buy
Analyst Ratings
6 Buy
0 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 6.81
(+36.75% Upside)
Medexus Pharmaceuticals Inc Earnings Call Summary for Q4/2026
- Q4 net revenue flat at $24.7M, but adjusted EBITDA surged 87% to $4.3M; operating income turned positive at $1.2M vs. $1.2M loss prior year.
- GRAFAPEX achieved cash flow accretion milestone in Q4; management guides fiscal 2027 product revenue to $30M-$32M, targeting $100M within five years.
- Company pivoted from diversified specialty pharma to rare disease/transplant focus; secured exclusive Canadian rights to UM171 cell therapy.
- Full-year revenue fell 8.3% to $99.3M on Gleolan loss and generic pressure, but gross margin improved to 54.8% from 52.2% on favorable mix.
- Stock declined 2.88% to $4.04 despite stronger profitability; cash fell to $6.5M from $24M, though net debt-to-EBITDA remains low at 0.95x.
Last Updated: 2026/06/26, 14:46
Read Full TranscriptEarnings
Latest Release
Nov 12, 2025
EPS / Forecast
-0,01 / --
Revenue / Forecast
24,74M / 43,02M
Compare MDP to Peers and Sector
Metrics to compare | MDP | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMDPPeersSector | |
|---|---|---|---|---|
P/E Ratio | −46.9x | −2.1x | −0.4x | |
PEG Ratio | 0.24 | 0.00 | 0.00 | |
Price/Book | 2.3x | 1.0x | 2.6x | |
Price / LTM Sales | 1.1x | 0.8x | 3.0x | |
Upside (Analyst Target) | 30.8% | 20.7% | 51.8% | |
Fair Value Upside | Unlock | 4.0% | 7.2% | Unlock |
Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on various therapeutic areas comprising allergy, dermatology, hematology, oncology, rheumatology, and rare diseases. Its primary products include IXINITY, an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis, psoriasis, and juvenile idiopathic arthritis; Rupall, a prescription allergy medication; and GRAFAPEX, an injection to treat allogeneic hematopoietic stem cell transplantation in adult and pediatric patients, acute myeloid leukemia (AML), and myelodysplastic syndrome. The company’s products portfolio also includes Cuvposa, a glycopyrrolate oral solution; Naproxen, a Pediapharm naproxen suspension; Otixal, a ciprofloxacin and flucinolone acetonide; and intraarticular, a triamcinolone hexacetonide injectable suspension. In addition, it offers over the counter products comprising Nyda, a topical treatment indicated for the eradication of head lice; Relaxa, an osmotic laxative to treat occasional constipation in adults; Oralvisc to reduce joint pain and enhance joint function in osteoarthritis of the knee; and Calcia Calcium and vitamin D products. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. was founded in 2000 and is based in Toronto, Canada.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Medexus Pharma (MDP) Stock Price Today?
The Medexus Pharma stock price today is 4,98 CAD.
What Stock Exchange Does Medexus Pharma Trade On?
Medexus Pharma is listed and trades on the Toronto Stock Exchange.
What Is the Stock Symbol for Medexus Pharma?
The stock symbol for Medexus Pharma is "MDP."
What Is the Medexus Pharma Market Cap?
As of today, Medexus Pharma market cap is 157,35M CAD.
What Is Medexus Pharma's Earnings Per Share (TTM)?
The Medexus Pharma EPS (TTM) is -0,07.
From a Technical Analysis Perspective, Is MDP a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Medexus Pharma Stock Split?
Medexus Pharma has split 2 times.
How Many Employees Does Medexus Pharma Have?
Medexus Pharma has 90 employees.
What is the current trading status of Medexus Pharma (MDP)?
As of Aug 06, 2026, Medexus Pharma (MDP) is trading at a price of 4,98 CAD, with a previous close of 4,97 CAD. The stock has fluctuated within a day range of 4,94 CAD to 5,01 CAD, while its 52-week range spans from 2,47 CAD to 5,25 CAD.
What Is Medexus Pharma (MDP) Price Target According to Analysts?
The average 12-month price target for Medexus Pharma is 6,81 CAD, with a high estimate of 8 CAD and a low estimate of 5.55 CAD. 6 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +36,75% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.